CURRICULUM VITAE ET STUDIORUM
2019

ARMANDO BARTOLAZZI
(ANAGRAFICA E RIASSUNTO DATI SALIENTI)

Name: ARMANDO BARTOLAZZI
Date of Birth: 11th February 1961;
Address: Dept. of Pathology St. Andrea University Hospital, piano –3; via di Grottarossa 1035 – 00189 Rome, Italy

Telephone: 9999999999999
Fax: +39888888888888 mobile: 8888888888
E-mail: 88888888888888888888
Indirizzo E Mail PEC: armbar@omceoromapec.it

CURRENT POSITION

November 2001-Today:
Dirigente First Level (Prof. of Pathology), ***with high specialized profile named "coordination for histological diagnosis of skin, thyroid and head-neck cancers"(IPAS 1- 40 punti)***,
St. Andrea University Hospital, Rome, Italy (*Permanent Position*) (via di grottarossa 1035 - 00189 Rome, Italy, Public Institution). * see specific certificate

Research Associate Department of Oncology-Pathology Cancer Center Karolinska, Karolinska Hospital, Stockholm Sweden. (CCK R8:04 – 17176 Solna, Sweden - Public Institution and University Medical School)

- Since November 2019: **Elected President of the National Scientific Committee of L.I.L.T.** (Lega Italiana per la Lotta ai Tumori)

PREVIOUS POSITIONS
June 2018 – August 2019:- **Undesecretary of State, Italian Ministry of Health**

May 1999- November 2001: Visiting Scientist and P.I. at Department of Oncology-Pathology, Cellular and Molecular Tumor Pathology, ***Cancer Centre Karolinska, CCK R8:04 Karolinska Hospital, Stockholm,*** Sweden (Prof. Olle Larsson Lab.) (Public Cancer Institution and University Hospital)

Roma 10 Giugno 2020

Azienda Ospedaliera Sant'Andrea
U.O. Anatomia Patologica
Dott. Armando Bartolazzi
9191209190306105

1994-01 Assistant Professor of Pathology (Dirigente I livello), Department of Pathology ***National Cancer Institute Regina Elena, IRCCS,*** viale Regina Elena 291 - 00100 Rome, Italy *(Permanent position). (National Cancer Institute)*

1993-94: - Post-doctoral fellow, at the Pathology Research Laboratory, ***Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston MA***, (USA). (Prof. Ivan Stamenkovic Lab.) *(Public /Privat Institution, Harvard University Boston- USA)*

Since 1994**:** P.I. of an independent research group at the NCI Regina Elena of Rome (IRCCS) and presently at St. Andrea University Hospital of Rome, focused **on Cancer Research and Translational Research in Pathology and Oncology**. (National Cancer Institute) – via delle Messi D'Oro Centro di Ricerca Sperimentale – 00167 Rome, Italy

1988-92: Research fellow at the Immunology Laboratory, National Cancer Institute, Regina Elena of Rome (IRCCS), Italy. PhD Program in Clinical and Experimental Oncology (Prof. P.G. Natali lab.) via delle Messi D'Oro Centro di Ricerca Sperimentale – 00167- Rome, Italy *(National Cancer Institute)*

EDUCATION

1999- Specialist Degree in Histology and Anatomic Pathology (1994-1999), with final thesis and Diploma (*summa cum laude)*. University "La Sapienza" of Rome, Italy (Title: Galectin-3 and Thyroid Cancer). Rome 24-11-1999

-

1993-94: - Post-Doctoral fellow, at the Pathology Research Laboratory, Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, (USA). (Ivan Stamenkovic Lab.)

1991: Specialist Degree in Clinical and Experimental Oncology with Ph.D. program (1987-1991) with final dissertation and Diploma (*summa cum laude*). National Cancer institute Regina Elena Rome, IRCCS and University "La Sapienza", Rome, Italy (Title: Production and characterization of monoclonal antibodies to Vla-3 integrin).- Rome 28-10-1991

1987-1988: Internship in Internal Medicine, I° Clinica Medica
Policlinico Umberto I, University "La Sapienza", Rome, Italy.

1987: M.D. license, University "La Sapienza", Rome, Italy. - Rome 15-10-1994.

1987: M.D. Degree University "La Sapienza", Rome, Italy, (*Summa cum laude*). (Thesis: Epidemiology of Endometrial Cancer in Italy. Prof. Giuseppe Atlante) Rome 10-4-1987

CLINICAL COMPETENCE AND FORMAL TRAINING
(Completed clinical training documented through specialist competence).

Number of years as specialist, and experience in inpatient and outpatient care.
The applicant worked since 1991 as specialist in Oncology in particular in the area of diagnosis and follow-up of cancer patients (Outpatient care).

From December 1993 to October 2001: Assistant Professor of Pathology at the National Cancer Institute Regina Elena of Rome IRCCS (*permanent position*). (40.000 histological slides/year, 9000 intra-operative diagnosis/year for five pathologists at the Department - Two years work experience were matured at the Cytology Department (Inpatient and outpatient care)

January 1997- March 99: designed pathologist for the multi-disciplinary clinical and experimental working group on Breast Cancer (600 cases/year) at the National Cancer Institute, Regina Elena of Rome. (Inpatient and outpatient care).

January 1997- March 99: designed pathologist for the multi-disciplinary clinical and experimental working group on Colon Cancer (180 cases/year) at the National Cancer Institute, Regina Elena of Rome (Inpatient and outpatient care).

January 1997- March 99: designed pathologist for the multi-disciplinary clinical and experimental working group on Melanoma (110 cases/year), at the National Cancer Institute, Regina Elena of Rome (Inpatient and outpatient care).

January 1996- March 99: designed pathologist for the autopsy service at the National Cancer Institute, Regina Elena of Rome.

1996-1998: Consultant Pathologist at the General Hospital S.S. Salvatore, (Regional Hospital), USL RM/25 Rome, Italy (Inpatient and outpatient care; 5155 histological diagnosis, personally signed).

2001: Consultant Pathologist for melanoma at Dept. of Oncology-Pathology Karolinska Hospital, Stockholm, Sweden.

1.
Since November 2001-present: Dirigente Primo Livello (Professor of Pathology) Sant' Andrea University Hospital, II° Faculty of Medicine, University Sapienza, Rome, Italy (about 12.000 histological cases / year)), with high specialized profile in Thyroid Pathology; starting from 03/2019 - IPAS-1 ***"coordination for histological diagnosis of skin, thyroid and head-neck cancers"(IPAS 1- 40 points),*** (*permanent position*). * (see enclosed certification)

Experience of on-call services

26 years experience of on-call services for intra-operative diagnosis (histological diagnosis on frozen tissue sections) (NCI Regina Elena and Sant' Andrea University Hospital, Rome, Italy).

SPECIAL CLINICAL COMPETENCE/PROFILE AREA

- Tumor Pathology (subspecialty expertise in Head and Neck Cancer, Thyroid cancer and Skin Cancer including Melanoma).
-Diagnosis in Oncology (clinical and histopathological diagnosis, immunodiagnosis, molecular diagnosis).
-Intra-operative histological diagnosis.
- Autoptic diagnosis.
-Clinical management of cancer patients during the diagnostic phase and follow-up.

*** IMPORTANT:**

The following table shows the results of the cumulative diagnostic activity at the Department of Pathology, St. Andrea Hospital, performed during the last 14 years (definitive diagnostic reports signed by the applicant). This table has been downloaded from the Official WIN-SAP program archive of the Institute.

Years 2005-2019 (January 1st; December 31st)

year	Diagnostic reports signed By A.B.	Total diagnostic activity at the Department	
2005	2417	11187	
2006	2793	12508	
2007	1912	12830	
2008	2191	14139	
2009	2551	14904	
2010	2600	14752	
2011	2709	15191	
2012	2961	15845	
2013	3062	16191	
2014	2844	16373	
2015	2591	15903	
2016	2455	12771	
2017	2452	13215	
2018*	1270	13821	* Undersecretary of State Italian Ministry of Health (by June 2018-Sept 2019)
2019*	0		

Total diagnostic activity	**34.808**	**199.630**	

In this work environment play seven senior pathologists and four young pathologists in training (residents in surgical pathology).

* During 2018-2019 Undersecretary of State Ministry of Health

Vedi Certificazione in originale rilasciata dalle competenti Direzione Sanitarie, in allegato

SPECIAL EXPERIMENTAL COMPETENCE / PROFILE AREA

-Translational research in Oncology and Pathology: 30 years of experience in production, characterization and clinical applications of monoclonal antibodies directed to tumor associated antigens. Some of these reagents are routinely used in several National and International Institutions for immuno-diagnosis, differential diagnosis of neoplastic diseases, for characterizing cancers of unknown origin and for evaluating intra- and post-operatively the minimal residual disease.
The recently developed ***galectin-3 thyrotest for the preoperative characterization of thyroid nodules*** (commercially available) has been developed, validated at international level by the applicant and translated in the clinical setting . The method is ***used worldwide for diagnosis of thyroid cancer*** (see specific scientific portfolio for details).

The Department of Pathology and Immunology of the NCI Regina Elena of Rome, in which the applicant worked for many years, has been the datum point for production, characterization and clinical application of mAbs for both National and International Institutions and Research Companies. In this work environment the applicant contributed to develop and organize one of the first human tissue bank and cell culture bank in Italy (reference Prof. Pier Giorgio Natali, past Scientific Director of the NCI of Rome and Head of the Immunology Laboratory.

COMMISSIONS OF TRUST

1998-2001, Elected member of the Scientific and Technical Committee (STC) at the National Cancer Institute Regina Elena, IRCCS, Rome. Italy.

OTHER MERITS

Credits from the Italian Minister of Public Health, Work and Social Politics for the Clinical and Scientific activities on Thyroid Cancer, Rome, February 13th, 2009

Selected by AIRC (Italian Association for Cancer Research) as one of the best 12 researchers providing significative scientific contribution in the Cancer field for the year 2008 ***(Repubblica November 4th , 2008; Repubblica e Corriere della Sera July 28th, 2008).***

-Since year 2000: Member of the Commission of experts for evaluation of EU grants applications (Ref: EE1998 1B02438) (on call).

- Since 2001 Life Member of UICC "International Union against Cancer"

- Since November 2019: Elected President of the National Scientific Committee of L.I.L.T. (Lega Italiana per la Lotta ai Tumori)

Other Merits and Qualifications

National Abilitation Full-Professor Anatomic Pathology-Surgical Pathology MED 08 (Bando 2012)

National Abilitation Full-Professor General Pathology MED 04 (Bando 2012)

Thyroid Cancer Expert nomination: World Health Organization (Lyon cedex DB, France) – WHO expert for Thyroid Cancer , June 30, 2015

From February 2015 listed on TIS –Top Italian Scientists - Via-Academy http://www.via-academy.org

September 2018, September 2019: President of the 68th session of the WHO regional Committee for Europe;

June 2018- August 2019 – Undersecretary of State Italian Ministry of Health

- GURU: (Deleghe)

-

- Art. 1.

- 1. **Il Sottosegretario di Stato prof. Armando Bartolazzi è delegato alla trattazione e alla firma degli atti relativi: a) all'attività di monitoraggio e di valutazione dei risultati nel campo della ricerca scientifica e tecnologica in materia sanitaria;**

-

- b) alle materie relative all'organizzazione delle attività connesse alla valutazione delle professioni sanitarie del Servizio sanitario nazionale e relativo contenzioso;

-

- c) alle competenze in materia di relazioni tra il Ministero della salute e le organizzazioni sindacali, ove il Ministro non intenda attendervi personalmente;

-

- d) alla tenuta dei rapporti tra il Servizio sanitario nazionale e le università in materia di personale delle aziende ospedaliero-universitarie;

-

- e) al coordinamento delle attività relative all'organizzazione del 68° Comitato regionale dell'Ufficio regionale per l'Europa dell'Organizzazione mondiale della sanità;

-

- f) ai procedimenti concernenti forme e condizioni particolari di autonomia.

-

- 2. Al fine di assicurare il coordinamento tra le attività espletate in base alla presente delega e gli obiettivi, i programmi e i progetti deliberati dal Ministro, il Sottosegretario
- di Stato prof. Armando Bartolazzi opera in costante raccordo con il ministro stesso.

-

- 3. Nelle materie delegate, il Sottosegretario di Stato prof. Armando Bartolazzi firma i relativi atti e provvedimenti; tali atti sono inviati alla firma per il tramite dell'Ufficio di Gabinetto.

-

- Art. 2.

- 1. Il Sottosegretario di Stato prof. Armando Bartolazzi è delegato a rappresentare il Ministro presso le Camere, nel rispetto delle direttive eventualmente fornite dal ministro e sempre che quest'ultimo non ritenga di attendervi personalmente, per lo svolgimento di interrogazioni a risposta orale e per ogni altro intervento che si renda necessario nel corso dei lavori parlamentari con riferimento alle materie di cui all'art. 1 e a ogni altra materia che il Ministro intenda di volta in volta affidare al medesimo sottosegretario di Stato.

-

- 2. Con riferimento alle materie di cui all'art. 1, al Sottosegretario di Stato prof. Armando Bartolazzi è delegata: a) la partecipazione alle Conferenze unificata, Stato-regionie Stato-
- città e autonomie locali, salvo che il ministro non ritenga di attendervi personalmente;
- b) la firma delle risposte alle interrogazioni a risposta scritta; c) la firma delle richieste di parere al Consiglio di Stato e ad altri organi istituzionali su questioni che non rivestono carattere generale o di principio.

REFEREE ACTIVITY

The Lancet
Journal of Experimental Medicine
Cancer Research
Journal of Clinical Oncology
International Journal of Cancer
American Journal of Pathology
European Journal of Cancer
British Journal of Cancer
British Journal of Dermatology
PLoS One
Thyroid
Journal of Endocrinology Investigation
Molecular Endocrinology
Histopathology
Journal Biological Chemistry
Journal of the American Academy of Dermathologists (JAAD)
International Journal of Molecular Science
Others.....

Rare Tumors **(Editorial Board)**
International Journal of Molecular Sciences (**Guest Editor**- special issue) 2017-2018 and 2018-2019

- **PATENTS**

Anticorpi monoclonali anti-galectina-3 radio marcati per visualizzazione e radio ablazione in vivo di tumori galectina-3 positivi

Inventor: Armando Bartolazzi

Co-inventors: Francesco Scopinaro; Alberto Signore; Rome February 2nd 2008, Patent. N. RM2008A000097

Grants: Since 1994 the applicant was granted with about 1.263.000,00 euro for cancer research projects, from several National and International Agencies .

PUBLICATIONS

Author of more than 110 Scientific publications in International Journals

Total amount of quotations in scientific publications and a list of the top 20 papers

Total citations: >5000 (110 publications total). Fonte Google Scholar
H-index: 36 (2020)

1. **Bartolazzi, A.,** Mottolese, M., Vocaturo, A., Bigotti, A., Vocaturo, G., Atlante, G., Prat, M and Natali, PG. (1991). Expression of CAR-3 and TAG-72 macromolecules in normal and transformed endometrium. Potential diagnostic application in postmenopausal age. Cancer Res. 51, pp. 3001-3005.

2. **Bartolazzi, A.**, Peach, R., Aruffo, A., and Stamenkovic, I. (1994). CD44-hyaluronate interaction is implicated in the regulation of tumor growth. J. Exp. Med. 180, pp. 53-66.

3. **Bartolazzi, A.**, Jackson, D., Bennett, K., Aruffo, A., Dickinson, R., Shields, J., Whittle, N. and Stamenkovic, I. (1995). Regulation of growth and dissemination of a human lymphoma by CD44 splice variants. J. Cell Sci. 108, pp. 1723-1733.

4. Bennett, KL., Modrell, B., Greenfield, B., **Bartolazzi, A.**, Stamenkovic, I., Peach, R., Jackson, G., Spring, F. and Aruffo, A. (1995). Regulation of CD44 binding to hyaluronan by glycosylation of variably spliced exons. J. Cell Biol. 131, pp. 1623-1633.

5. **Bartolazzi, A.**, Nocks, A., Aruffo, A., Spring, F., and Stamenkovic, I. (1996). Glycosylation of CD44 is implicated in CD44-mediated cell adhesion to hyaluronan. J. Cell Biol. 132, pp. 1199-1208.

6. Martegani, M.P., Del Prete, F., Gasbarri, A., Natali, P.G., and **Bartolazzi, A.** (1999). Structural variability of CD44v molecules and reliability of immunodetection of CD44 isoforms, using mAbs specific for CD44 variant exon products. Am. J. Pathol. 154, pp. 291-300.

7. Gasbarri, A., Martegani, M.P., Del Prete, F., Lucante, T. Natali, P.G. and **Bartolazzi, A.** (1999): Galectin-3 and CD44v6 isoforms in the pre-operative evaluation of thyroid nodules. J. Clin. Oncol.17, pp. 3494-3502.

8. **Bartolazzi A.** (2000): Improving accuracy of cytology for nodular thyroid lesions The Lancet 355:1661-1662.

9. Girnita, L., Girnita, A., Brodin, B., Xie, Y., Nilsson, G., Lundeberg, J., Wejde, J., **Bartolazzi, A.**, Wiman, C., and Larsson, O. (2000): Increased expression of Insulin-like

growth factor-1 receptor (IGF-1R) in malignant cells expressing aberrant p53. Functional impact. Cancer Res. 60:5278-5283.

10. **Bartolazzi, A.**, Gasbarri, A., Papotti, M., Bussolati, G., Lucante, T., Khan, A., Inohara, H., Marandino, F., Orlandi, F., Nardi, F., Vecchione, A., Larsson, O., and the Thyroid Cancer Study Group. (2001). Application of an immunodiagnostic method for improving the preoperative diagnosis of nodular thyroid lesions. The Lancet 357: 1644-50.

11. Sjolin H., Tomasello E., Mousavi-Jazi M., **Bartolazzi A.**, Vivier E., Karre K., and Cerboni C. (2002): Pivotal role of KARAP/DAP12 adaptor molecule in the natural killer cell-mediated resistance to murine cytomegalovirus infection. J. Exp. Med. 195:825-834.

12. Xie Y., Skytting B., Nilsson G., Gasbarri A., Haslam K., **Bartolazzi A.**, Brodin B., Mandahl N., and Larsson O. (2002): SYT-SSX fusion gene is critical for expression of cyclin D1 in synovial sarcoma cells. Cancer Res. 62:3861-3867.

13. Girnita A, Girnita L, del Prete F, **Bartolazzi A**, Larsson O, Axelson M. (2004). Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res. 64:236-42.

14. Papotti M, Rodriguez J, Pompa RD, **Bartolazzi A**, Rosai J. (2005).
Galectin-3 and HBME-1 expression in well-differentiated thyroid tumors with follicular architecture of uncertain malignant potential. Mod Pathol. 18:541-6.

15. B. Cecchinelli, L. Lavra, C. Rinaldo, S. Iacovelli, A. Gurtner, A. Gasbarri, A. Ulivieri, F. del Prete, M. Trovato, G Piaggio, **A. Bartolazzi,*** S. Soddu, & S. Sciacchitano. (2006). Repression of the antiapoptotic molecule Galectin-3 by homeodomain-interactin protein kinase 2-activated p53 is required for p53-induced apoptosis. Mol Cell Biol 26:4746-57. *(* Corresponding author)*

16. **Bartolazzi A**, Orlandi F, Saggiorato E, Volante M, Arecco F, Rossetto R, Palestini N, Ghigo E, Papotti M, Bussolati G, Martegani MP, Pantellini F, Carpi A, Giovagnoli MR, Monti S, Toscano V, Sciacchitano S, Pennelli GM, Mian C, Pelizzo MR, Rugge M, Troncone G, Palombini L, Chiappetta G, Botti G, Vecchione A, Bellocco R; Italian Thyroid Cancer Study Group (ITCSG). (2008). Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study. The Lancet Oncol. 9(6): 543-9. Epub 2008 May 19.

17. **Bartolazzi A**, D'Alessandria C, Parisella MG, Signore A, Del Prete F, Lavra L, Braesch-Andersen S, Massari R, Trotta C, Soluri A, Sciacchitano S, Scopinaro F. (2008). Thyroid cancer imaging in vivo by targeting the anti-apoptotic molecule galectin-3. PLoS ONE. 3(11): e3768. Epub 2008 Nov20.

18. Rinaldo C, Moncada A, Gradi A, Ciuffini L, D'Eliseo D, Siepi F, Prodosmo A, Giorgi A, Pierantoni GM, Trapasso F, Guarguaglini G, **Bartolazzi A**, Cundari E, Schininà ME, Fusco A, Soddu S. HIPK2 controls cytokinesis and prevents tetraploidization by phosphorylating histone H2B at the midbody. Mol Cell. 2012 Jul 13;47(1):87-98. doi: 10.1016/j.molcel.2012.04.029. Epub 2012 May 31.

19. Valente D, Bossi G, Moncada A, Tornincasa M, Indelicato S, Piscuoglio S, Karamitopoulou ED, **Bartolazzi A**, Pierantoni GM, Fusco A, Soddu S, Rinaldo C.
HIPK2 deficiency causes chromosomal instability by cytokinesis failure and increases tumorigenicity. Oncotarget. 2015 Apr 30;6(12):10320-34.

20. D'Alessandria C, Braesch-Andersen S, Bejo K, Reder S, Blechert B, Schwaiger M, **Bartolazzi A.** Noninvasive In Vivo Imaging and Biologic Characterization of Thyroid Tumors by ImmunoPET Targeting of Galectin-3. Cancer Res. 2016 Jun 15;76(12):3583-92. doi: 10.1158/0008-5472.CAN-15-3046. Epub 2016 May 23.

Le restanti pubblicazioni internazionali possono essere visualizzate ed eventualmente scaricate direttamente in originale dal sito ufficiale PubMed
https://www.ncbi.nlm.nih.gov/pubmed
US National Library of Medicine - NIH

VEDI PORTAFOGLI SPECIFICI IN ALLEGATO

ELENCO DEI DOCUMENTI E DEI TITOLI PRESENTATI

1) **Domanda di partecipazione al concorso, copia documento e ricevuta versamento 10 euro**

2) **Curriculum Vitae (con dichiarazione sostitutiva atto di notorietà) costituito da:**

2a-2abis): Sezione anagrafica e riassunto dati salienti (pag. 1-11) + 20 pubblicazioni selezionate per estenso (top) autocertificate

2b) -PORTAFOGLIO SCIENTIFICO (pag. 12-41)

2c)- PORTAFOGLIO PEDAGOGICO (pag. 42-50)

2d)- PORTAFOGLIO CLINICO (pag. 51-57)

2e)- PORTAFOGLIO PER LA VALUTAZIONE DELLE CAPACITA' GESTIONALI, LEADERSHIP, SVILUPPO E RELAZIONI NEL POSTO DI LAVORO (pag 58-65)

- *e relativa dichiarazione sostitutiva atto di notorietà*

-

3) **Certificazioni diploma di laurea e di specializzazioni**

- Diploma di Laurea

- Diploma di Abilitazione

- Diploma di Specializzazione in Oncologia Clinica

- Certificato sostitutivo del Diploma di Specializzazione in Anatomia ed Istologia Patologica.

e relativa dichiarazione sostitutiva di certificazione

4) **CERTIFICATI DI SERVIZIO ALTRI REQUISITI SPECIFICI:**

- Certificato di Servizio e RESOCONTO ATTIVITA DIAGNOSTICA redatto dall' Azienda Ospedaliera Sant'Andrea (dal 16-11-2001, ad oggi)

- DELIBERA incarico di Alta Specializzazione

- DELIBERA Comitato Unico di Garanzia AOSA

Azienda Ospedaliera Sant'Andrea
U.O. Anatomia Patologica
Dott. Armando Bartolazzi
9191209190300103

- Certificato della Commissione Europea inserimento nella lista "Valutatori Esperti, Ricerca Scientifica e Sviluppo".

- Certificazione nomina elettiva a Presidente del Comitato Scientifico Nazionale e della Commissione per la valutazione dei Progetti di Ricerca LILT

e relativa dichiarazione sostitutiva di certificazioni

5) DOCUMENTI ATTESTANTI IDONEITA' A POSIZIONI APICALI CLINICHE E DI RICERCA OTTENUTE IN COMPETIZIONI INTERNAZIONALI – ABILITAZIONI-

- Certificato di idoneità a Direttore di Struttura Complessa di Anatomia ed Istologia Patologica presso l'Istituto Tumori di Genova.

- Documenti attestanti l'idoneità a ricoprire il ruolo professore Ordinario di Anatomia Patologica presso il Karolinska Hospital di Stoccolma, Svezia (valutazione comparativa tra I candidati)

- Documenti attestanti l'idoneità a ricoprire il posto di Project Leader in Biomedicine presso il Karolinska Institute di Stoccolma, Svezia (valutazione comparativa in dettaglio).

-Abilitazione Scientifica Nazionale a Professore Ordinario di Patologia Generale

- Abilitazione Scientifica Nazionale a Professore Ordinario di Anatomia Patologica

e relativa dichiarazione sostitutiva di certificazioni

6) Certificazioni di docenza

- n. 6 certificati in copia conforme agli originali

- n.2 certificazioni attività svolte presso il CRS ifo

e relativa dichiarazione sostitutiva di certificazioni

-

7) **LETTERE DI REFERENZE DI AUTORITA' INTERNAZIONALI**

(3 documenti + referenze)

e relativa dichiarazione sostitutiva di certificazioni

8) **PUBBLICAZIONI RILEVANTI**

a) **- 4 pubblicazioni attestanti il trasferimento in pratica clinica del test diagnostico scoperto per I tumori tiroidei**

b) **- 4 pubblicazioni attestanti gli studi preclinici di tumor imaging in vivo, con una sonda brevettata, in fase di validazione per il trasferimento in pratica clinica. + attestazione brevetto**

c) **- 1 pubblicazione relativa al marcatore predittivo di risposta all'immunoterapia , recentemente identificato, in corso di valutazione multicentrica per il trasferimento in pratica clinica.**

d) **- Selezione di ulteriori 8 contributi scientifici di valore traslazionale prodotti nell'ultimo quinquennio –e frontespizio libro**

e relativa dichiarazione sostitutiva atto di notorietà

9) Breve rassegna stampa (42 pagine)

Roma 10 Novembre 2009

In Fede

Dr. Armando Bartolazzi

3/3

Nr. 20 pubblicazioni selezionate su attività di ricerca con valore traslazionale (+ Atto notorietà - Dichiarazione sostitutiva)

PUBLICATIONS

Author of more than 110 Scientific publications in International Journals

Total amount of quotations in scientific publications and a list of the top 20 papers

Total citations: >5000 (110 publications total). Fonte Google Scholar
H-index: 36 (2020)

1. **Bartolazzi, A.,** Mottolese, M., Vocaturo, A., Bigotti, A., Vocaturo, G., Atlante, G., Prat, M and Natali, PG. (1991). Expression of CAR-3 and TAG-72 macromolecules in normal and transformed endometrium. Potential diagnostic application in postmenopausal age. Cancer Res. 51, pp. 3001-3005.

2. **Bartolazzi, A.**, Peach, R., Aruffo, A., and Stamenkovic, I. (1994). CD44-hyaluronate interaction is implicated in the regulation of tumor growth. J. Exp. Med. 180, pp. 53-66.

3. **Bartolazzi, A.**, Jackson, D., Bennett, K., Aruffo, A., Dickinson, R., Shields, J., Whittle, N. and Stamenkovic, I. (1995). Regulation of growth and dissemination of a human lymphoma by CD44 splice variants. J. Cell Sci. 108, pp. 1723-1733.

4. Bennett, KL., Modrell, B., Greenfield, B., **Bartolazzi, A.**, Stamenkovic, I., Peach, R., Jackson, G., Spring, F. and Aruffo, A. (1995). Regulation of CD44 binding to hyaluronan by glycosylation of variably spliced exons. J. Cell Biol. 131, pp. 1623-1633.

5. **Bartolazzi, A.**, Nocks, A., Aruffo, A., Spring, F., and Stamenkovic, I. (1996). Glycosylation of CD44 is implicated in CD44-mediated cell adhesion to hyaluronan. J. Cell Biol. 132, pp. 1199-1208.

6. Martegani, M.P., Del Prete, F., Gasbarri, A., Natali, P.G., and **Bartolazzi, A.** (1999). Structural variability of CD44v molecules and reliability of immunodetection of CD44 isoforms, using mAbs specific for CD44 variant exon products. Am. J. Pathol. 154, pp. 291-300.

7. Gasbarri, A., Martegani, M.P., Del Prete, F., Lucante, T. Natali, P.G. and **Bartolazzi, A.** (1999): Galectin-3 and CD44v6 isoforms in the pre-operative evaluation of thyroid nodules. J. Clin. Oncol.17, pp. 3494-3502.

8. **Bartolazzi A.** (2000): Improving accuracy of cytology for nodular thyroid lesions The Lancet 355:1661-1662.

9. Girnita, L., Girnita, A., Brodin, B., Xie, Y., Nilsson, G., Lundeberg, J., Wejde, J., **Bartolazzi, A.**, Wiman, C., and Larsson, O. (2000): Increased expression of Insulin-like

growth factor-1 receptor (IGF-1R) in malignant cells expressing aberrant p53. Functional impact. Cancer Res. 60:5278-5283.

10. **Bartolazzi, A.**, Gasbarri, A., Papotti, M., Bussolati, G., Lucante, T., Khan, A., Inohara, H., Marandino, F., Orlandi, F., Nardi, F., Vecchione, A., Larsson, O., and the Thyroid Cancer Study Group. (2001). Application of an immunodiagnostic method for improving the preoperative diagnosis of nodular thyroid lesions. The Lancet 357: 1644-50.

11. Sjolin H., Tomasello E., Mousavi-Jazi M., **Bartolazzi A.**, Vivier E., Karre K., and Cerboni C. (2002): Pivotal role of KARAP/DAP12 adaptor molecule in the natural killer cell-mediated resistance to murine cytomegalovirus infection. J. Exp. Med. 195:825-834.

12. Xie Y., Skytting B., Nilsson G., Gasbarri A., Haslam K., **Bartolazzi A.**, Brodin B., Mandahl N., and Larsson O. (2002): SYT-SSX fusion gene is critical for expression of cyclin D1 in synovial sarcoma cells. Cancer Res. 62:3861-3867.

13. Girnita A, Girnita L, del Prete F, **Bartolazzi A**, Larsson O, Axelson M. (2004). Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res. 64:236-42.

14. Papotti M, Rodriguez J, Pompa RD, **Bartolazzi A**, Rosai J. (2005). Galectin-3 and HBME-1 expression in well-differentiated thyroid tumors with follicular architecture of uncertain malignant potential. Mod Pathol. 18:541-6.

15. B. Cecchinelli, L. Lavra, C. Rinaldo, S. Iacovelli, A. Gurtner, A. Gasbarri, A. Ulivieri, F. del Prete, M. Trovato, G Piaggio, **A. Bartolazzi,*** S. Soddu, & S. Sciacchitano. (2006). Repression of the antiapoptotic molecule Galectin-3 by homeodomain-interactin protein kinase 2-activated p53 is required for p53-induced apoptosis. Mol Cell Biol 26:4746-57. *(* Corresponding author)*

16. **Bartolazzi A**, Orlandi F, Saggiorato E, Volante M, Arecco F, Rossetto R, Palestini N, Ghigo E, Papotti M, Bussolati G, Martegani MP, Pantellini F, Carpi A, Giovagnoli MR, Monti S, Toscano V, Sciacchitano S, Pennelli GM, Mian C, Pelizzo MR, Rugge M, Troncone G, Palombini L, Chiappetta G, Botti G, Vecchione A, Bellocco R; Italian Thyroid Cancer Study Group (ITCSG). (2008). Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study. The Lancet Oncol. 9(6): 543-9. Epub 2008 May 19.

17. **Bartolazzi A**, D'Alessandria C, Parisella MG, Signore A, Del Prete F, Lavra L, Braesch-Andersen S, Massari R, Trotta C, Soluri A, Sciacchitano S, Scopinaro F. (2008). Thyroid cancer imaging in vivo by targeting the anti-apoptotic molecule galectin-3. PLoS ONE. 3(11): e3768. Epub 2008 Nov20.

18. Rinaldo C, Moncada A, Gradi A, Ciuffini L, D'Eliseo D, Siepi F, Prodosmo A, Giorgi A, Pierantoni GM, Trapasso F, Guarguaglini G, **Bartolazzi A**, Cundari E, Schininà ME, Fusco A, Soddu S. HIPK2 controls cytokinesis and prevents tetraploidization by phosphorylating histone H2B at the midbody. Mol Cell. 2012 Jul 13;47(1):87-98. doi: 10.1016/j.molcel.2012.04.029. Epub 2012 May 31.

19. Valente D, Bossi G, Moncada A, Tornincasa M, Indelicato S, Piscuoglio S, Karamitopoulou ED, **Bartolazzi A**, Pierantoni GM, Fusco A, Soddu S, Rinaldo C.
HIPK2 deficiency causes chromosomal instability by cytokinesis failure and increases tumorigenicity. Oncotarget. 2015 Apr 30;6(12):10320-34.

20. D'Alessandria C, Braesch-Andersen S, Bejo K, Reder S, Blechert B, Schwaiger M, **Bartolazzi A.** Noninvasive In Vivo Imaging and Biologic Characterization of Thyroid Tumors by ImmunoPET Targeting of Galectin-3. Cancer Res. 2016 Jun 15;76(12):3583-92. doi: 10.1158/0008-5472.CAN-15-3046. Epub 2016 May 23.

Le restanti pubblicazioni internazionali possono essere visualizzate ed eventualmente scaricate direttamente in originale dal sito ufficiale PubMed
https://www.ncbi.nlm.nih.gov/pubmed
US National Library of Medicine - NIH

VEDI PORTAFOGLI SPECIFICI IN ALLEGATO